Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03745898 · ClinicalTrials.gov registry record · Phase 3
The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients With Heart Failure and Central Sleep Apnea
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 98
- Enrollment target
NCT03745898 is a Phase 3 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 98 participants.
The verdict
NCT03745898, a Phase 3 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 98 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the long-term effects of Nocturnal Oxygen Therapy (NOXT) on the mortality and morbidity of patients with stable heart failure and a reduced ejection fraction (HFrEF), already receiving optimal guideline-directed medical therapy (GDMT), who have central sleep apnea (CSA).
Interventions
- DRUG Oxygen
- OTHER Room Air
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2022-06-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03745898
The ClinicalTrials.gov registry entry for NCT03745898 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxygen is the first listed.
NCT03745898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03745898 about?
NCT03745898 is a clinical study titled "The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients With Heart Failure and Central Sleep Apnea". The purpose of this trial is to evaluate the long-term effects of Nocturnal Oxygen Therapy (NOXT) on the mortality and morbidity of patients with stable heart failure and a reduced ejection fraction (HFrEF), already receiving optimal guideline-directed medical therapy (GDMT), who have central sleep ...
What is the current status of trial NCT03745898?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 98 participants. The study started on 2019-04-15. Estimated completion is 2022-06-17.
What interventions are being tested in trial NCT03745898?
The interventions under investigation include: Oxygen (DRUG), Room Air (OTHER).
Who is sponsoring clinical trial NCT03745898?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.